Top

International Journal of Clinical Oncology

Published in:

22-09-2023 | Kidney Cancer | Original Article

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

Authors: Shigemitsu Horie, Sei Naito, Shingo Hatakeyama, Shuya Kandori, Kazuyuki Numakura, Renpei Kato, Tomoyuki Koguchi, Shingo Myoen, Yoshihide Kawasaki, Akihiro Ito, Hisanobu Adachi, Yoshiyuki Kojima, Wataru Obara, Tomonori Habuchi, Hiroyuki Nishiyama, Chikara Ohyama, Norihiko Tsuchiya

Published in: International Journal of Clinical Oncology | Issue 11/2023

Abstract

Background

The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).

Methods

A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models.

Results

Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively.

Conclusion

The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.

Available only for authorised users

Dabestani S, Thorstenson A, Lindblad P et al (2016) Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 34(8):1081–1086. https://doi.org/10.1007/s00345-016-1773-y CrossRefPubMed

Cosso F, Roviello G, Nesi G et al (2016) Adjuvant therapy for renal cell carcinoma: hype or hope?. Int J Mol Sci. https://doi.org/10.3390/ijms24044243 CrossRef

Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. https://doi.org/10.1056/NEJMoa1611406 CrossRefPubMed

Motzer RJ, Ravaud A, Patard JJ et al (2018) Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol 73(1):62–68. https://doi.org/10.1016/j.eururo.2017.09.008 CrossRefPubMed

Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016. https://doi.org/10.1016/s0140-6736(16)00559-6 CrossRefPubMedPubMedCentral

Motzer RJ, Haas NB, Donskov F et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923. https://doi.org/10.1200/jco.2017.73.5324 CrossRefPubMedPubMedCentral

Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133–1144. https://doi.org/10.1016/s1470-2045(22)00487-9 CrossRefPubMed

Vogl UM, McDermott D, Powles T (2023) Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. Lancet. https://doi.org/10.1016/s0140-6736(22)02631-9 CrossRefPubMed

Pal SK, Uzzo R, Karam JA et al (2022) Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400(10358):1103–1116. https://doi.org/10.1016/s0140-6736(22)01658-0 CrossRefPubMed

10.

Haidar GM, Hicks TD, El-Sayed HF et al (2017) Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord 5(3):430–436. https://doi.org/10.1016/j.jvsv.2016.12.011 CrossRefPubMed

11.

Warren H, Fernando A, Thomas K et al (2019) Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International metastatic renal cell cancer database consortium (IMDC) score. BJU Int 124(3):462–468. https://doi.org/10.1111/bju.14755 CrossRefPubMed

12.

Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67 CrossRefPubMed

13.

Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6):1649–1657. https://doi.org/10.1200/jco.2001.19.6.1649 CrossRefPubMed

14.

Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400. https://doi.org/10.1097/01.ju.0000035885.91935.d5 CrossRefPubMed

15.

Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. https://doi.org/10.1002/cncr.11234 CrossRefPubMed

16.

Karakiewicz PI, Briganti A, Chun FK et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25(11):1316–1322. https://doi.org/10.1200/jco.2006.06.1218 CrossRefPubMed

17.

Cindolo L, de la Taille A, Messina G et al (2003) A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92(9):901–905. https://doi.org/10.1111/j.1464-410x.2003.04505.x CrossRefPubMed

18.

Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780. https://doi.org/10.1016/j.eururo.2018.01.005 CrossRefPubMed

19.

Mattila KE, Laajala TD, Tornberg SV et al (2021) A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Sci Rep 11(1):8650. https://doi.org/10.1038/s41598-021-88177-9 CrossRefPubMedPubMedCentral

20.

Dolan RD, Laird BJA, Klepstad P et al (2019) An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine 98(37):e17019. https://doi.org/10.1097/md.0000000000017019 CrossRefPubMedPubMedCentral

21.

Ruan GT, Xie HL, Zhang HY et al (2022) Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer. Clin Nutr 41(10):2284–2294. https://doi.org/10.1016/j.clnu.2022.08.025 CrossRefPubMed

22.

Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809 CrossRefPubMed

23.

Patel SH, Derweesh IH, Saito K et al (2021) Preoperative elevation of C-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: analysis from the international marker consortium renal cancer (INMARC). Clin Genitourin Cancer 19(4):e206–e215. https://doi.org/10.1016/j.clgc.2021.02.003 CrossRefPubMed

24.

Hu H, Yao X, Xie X et al (2017) Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol 35(2):261–270. https://doi.org/10.1007/s00345-016-1864-9 CrossRefPubMed

25.

Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57(2):317–325. https://doi.org/10.1016/j.eururo.2008.12.026 CrossRefPubMed

26.

Yasuda Y, Saito K, Yuasa T et al (2013) Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18(5):884–889. https://doi.org/10.1007/s10147-012-0454-0 CrossRefPubMed

27.

Semeniuk-Wojtas A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive Protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16(3):e685–e693. https://doi.org/10.1016/j.clgc.2018.01.010 CrossRefPubMed

28.

Santoni M, Buti S, Conti A et al (2015) Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 10(4):517–522. https://doi.org/10.1007/s11523-014-0356-3 CrossRefPubMed

29.

Tachibana H, Nemoto Y, Ishihara H et al (2022) Predictive impact of early changes in serum C-Reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 20(1):e81–e88. https://doi.org/10.1016/j.clgc.2021.10.005 CrossRefPubMed

Title: Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group
Authors: Shigemitsu Horie
Sei Naito
Shingo Hatakeyama
Shuya Kandori
Kazuyuki Numakura
Renpei Kato
Tomoyuki Koguchi
Shingo Myoen
Yoshihide Kawasaki
Akihiro Ito
Hisanobu Adachi
Yoshiyuki Kojima
Wataru Obara
Tomonori Habuchi
Hiroyuki Nishiyama
Chikara Ohyama
Norihiko Tsuchiya
Publication date: 22-09-2023
Publisher: Springer Nature Singapore
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Nephrectomy
Nephrectomy
Nephrectomy
Published in: International Journal of Clinical Oncology / Issue 11/2023
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-023-02401-2

European Society for Medical Oncology Congress 2023

NSCLC Video

ESMO23: Non-small-cell lung cancer highlights

Watch the panel discussion

Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2.

Supported by: F. Hoffmann-La Roche Ltd.

Dr. Luis Paz-Ares

Prof. Solange Peters

Dr. Marina Garassino

ESMO23: Small-cell lung cancer highlights

SCLC Expert Interview

Cancer of Unknown Primary: Key results from ESMO 2023

Cancer of Unknown Primary Expert Interview

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

25-10-2023 Cervical Cancer News

EV-302 heralds practice change for advanced urothelial cancer

24-10-2023 Urothelial Cancer News

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

23-10-2023 Thyroid Cancer News

» View more highlights on the ESMO 2023 hub page

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

Case-Based Insights: Oncology and Hematology Training Course

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

Case-Based Insights: Oncology and Hematology Training Course

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

Case-Based Insights: Oncology and Hematology Training Course

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

Case-Based Insights: Oncology and Hematology Training Course

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

Abstract

Background

Methods

Results

Conclusion

European Society for Medical Oncology Congress 2023

ESMO23: Non-small-cell lung cancer highlights

ESMO23: Small-cell lung cancer highlights

Cancer of Unknown Primary: Key results from ESMO 2023

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

EV-302 heralds practice change for advanced urothelial cancer

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

» View more highlights on the ESMO 2023 hub page

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

48/♀ with increasing spontaneous haematomas all over her body – Case 37

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR-300/RGMB axis

Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer

Correction to: Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR‑300/RGMB axis

Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer

Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model

Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial

European Society for Medical Oncology Congress 2023

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases